Previous 10 | Next 10 |
APX3330 has the Potential to be a Novel Oral Treatment Option with Dual Mechanism of Anti-VEGF and Anti-Inflammatory for Diabetic Retinopathy Top Line Data from ZETA-1 Expected by Early 2022 FARMINGTON HILLS, Mich., April 08, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma,...
Nano-X Imaging (NNOX) +68% as FDA OKs 510(k) for Single Source Nanox.ARC Digital X-Ray.Chembio Diagnostics (CEMI) +48%.NanoVibronix (NAOV) +24%.Leaf Group Ltd. (LEAF) +19% on being acquired by Graham Holdings for $8.50 per share.dMY Technology Group (DMYD) +19%.Hoth Therapeutics (HO...
FARMINGTON HILLS, Mich., April 01, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, approved an equity award under Ocuphire’s Inducement Plan,...
Universe Pharmaceuticals (UPC) +113%.Humanigen (HGEN) +61% on positive Phase 3 data for COVID-19 therapy.Cyanotech Corporation (CYAN) +48%.Big Rock Partners Acquisition (BRPA) +42%.SeaChange International (SEAC) +34% on multi-million-dollar contract with broadband service provider.F...
The following slide deck was published by Ocuphire Pharma, Inc. in conjunction with this event. For further details see: Ocuphire Pharma (OCUP) Investor Presentation - Slideshow
Gainers: SunLink Health Systems (SSY) +161%, Can-Fite BioPharma (CANF) +61%, Streamline Health Solutions (STRM) +56%, Anchiano Therapeutics (ANCN) +40%, Enzo Biochem (ENZ) +39%.Losers: Solid Biosciences (SLDB) -31%, Zynerba Pharmaceu...
CleanSpark (CLSK) -24% on raising $200M capital via equity offering.Takung Art (TKAT) -20%.Oriental Culture Holding (OCG) -24%.Sigma Labs (SGLB) -16%.Zynerba Pharmaceuticals (ZYNE) -14%.Solid Biosciences (SLDB) -15% after reports mid-stage data in Duchenne muscular dystrop...
Can These Top Health Care Stocks Keep Up Their Momentum This Week? The health care sector continues to play a critical role in the economy. This could mean well for investors who have invested in health care stocks . Despite the pandemic placing an enormous strain on the global ...
Cantor Fitzgerald has upgraded the price target of Ocuphire Pharma ([[OCUP]] -3.0%) following the positive top-line results announced by the company today in the MIRA-2 Phase 3 registration trial for Nyxol in the reversal of pharmacologically induced mydriasis.With a ~33.3% raise, t...
Intec Pharma Ltd (NTEC) +142% on announcing merger agreement with Decoy Biosystems.Check-Cap Ltd. (CHEK) +113% after receiving FDA IDE approval for pivotal study of C-Scan®.Acer Therapeutics (ACER) +67%.Shaw Communications (SJR) +55% as Rogers to acquire the company in C$2...
News, Short Squeeze, Breakout and More Instantly...
Ocuphire Pharma Inc Com Company Name:
OCUP Stock Symbol:
NASDAQ Market:
Ocuphire Pharma Inc Com Website:
CEO to participate in ARVO SIG panel on oral medications for retinal diseases ZETA-1 Phase 2 clinical trial subset analysis to be presented during the ASRS 42 nd Annual Scientific Meeting FARMINGTON HILLS, Mich., July 10, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (N...
FARMINGTON HILLS, Mich., June 06, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing small molecule therapies for the treatment of patients with retinal and refractive eye disorders, today anno...
FARMINGTON HILLS, Mich., May 10, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing small molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced financial r...